<DOC>
	<DOCNO>NCT00315432</DOCNO>
	<brief_summary>The purpose study describe time course extent hemoglobin ( Hb ) change erythropoietic response PEG-IFN/RBV ( Pegylated Interferon Ribavirin ) -induced anemia In HCV ( hepatitis C virus ) /HIV ( human immunodeficiency virus ) co-Infected subject .</brief_summary>
	<brief_title>NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection</brief_title>
	<detailed_description>Patients receive combination therapy chronic hepatitis C virus ( HCV ) infection ( standard pegylated interferon alfa [ PEG-IFN ] combination ribavirin [ RBV ] ) frequently develop moderate severe anemia . In large , prospective , clinical trial PEG-IFN alfa-2b PEG-IFN alfa-2a , report mean decrease hemoglobin ( Hb ) 2.5 g/dL , 3.7 g/dL , respectively . Furthermore , retrospective study , 54 % standard interferon/RBV-treated patient hemoglobin decrease least 3 g/dL . It important understand cause , natural history , risk factor associate HCV therapy-induced anemia , decrease hemoglobin result RBV dose reduction discontinuation , may decrease likelihood virologic response patient . Erythropoietin endogenous hormone act bone marrow increase number erythroid progenitor cell ( red blood cell ) . Normally , decrease hemoglobin level accompany increase serum erythropoietin ( sEPO ) level , ultimately normalize Hemoglobin level . The relationship hemoglobin serum erythropoietin le apparent patient chronic disease cancer human immunodeficiency virus ( HIV ) infection . It know whether HCV/HIV co-infected patient receive combination PEG-IFN/RBV therapy similarly diminish erythropoietic response anemia . The objective study document pattern hemoglobin change erythropoietic response ( baseline final assessment ) HCV/HIV co-infected patient receive combination therapy IFN / RBV . N/A</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>HIV infect patient confirm HIVRNA level HCV infect patient confirm PCR ( polymerase chain reaction ) branch DNA ( bDNA ) Scheduled commence combination IFN/RBV therapy Day 1 Normal serum creatinine On stable antiretroviral regimen ( HIV ) least 4 week Life expectancy &gt; 6 month Patients history primary hematologic disease Anemia attributable factor iron folate deficiency , pretreatment hemolysis gastrointestinal bleeding Has suspect confirm significant hepatic disease etiology HCV ( e.g . alcohol , HBV DNA , autoimmune disease etc )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Natural History , Hepatitis C Infection , HIV Infection , HCV/HIV co-infection Ribavirin , Pegylated Interferon , Interferon</keyword>
</DOC>